Objectif
This icovid project is the continuation of the pro bono icovid initiative that developed the CE-marked and FDA permitted AI-based CT analysis software, icolung, and made it available in over 65 hospitals worldwide. The icovid project aims to improve the software making it of greater value as the clinical needs evolve, validating it in renowned academic centers and deploying it at large-scale across Europe. icolung is expected to have a significant societal impact by increasing confidence when making a CT diagnosis and providing accurate quantification of disease and prognostic information in patients with suspected COVID-19 disease. Importantly, even in a low prevalence setting icolung may have a much higher sensitivity and a comparable specificity for the diagnosis compared to the RT-PCR testing used currently. Identifying infected patients earlier will reduce the risk of further contamination and allows the right patient management to start earlier. icolung also predicts the risk of developing severe COVID-19 disease for which ICU admission and mechanical ventilation are required, allowing optimization of patient care. This project will significantly strengthen the position of two European SMEs in the rapidly growing market of AI in healthcare. One of them is coordinating the project and the consortium involved, enabling quick responses in a rapidly changing environment. The consortium builds further on existing organic collaboration and contains world-renowned experts of which multiple are part of the Executive Committee of the European Society of Thoracic Imaging.
Champ scientifique
Programme(s)
Appel à propositions
H2020-SC1-PHE-CORONAVIRUS-2020-2
Voir d’autres projets de cet appelSous appel
H2020-SC1-PHE-CORONAVIRUS-2020-2-CNECT
Régime de financement
IA - Innovation actionCoordinateur
3012 Leuven
Belgique
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.